VACCINEX, INC.
VCNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VCNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VCNX
Vaccinex, Inc. is a clinical-stage biotechnology company developing targeted biotherapeutics, primarily its lead candidate pepinemab, for neurodegenerative diseases, cancer, and autoimmune disorders, with a focus on Alzheimer's disease and head and neck cancer.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2024.
Tracking 3 pipeline candidates · 1 clinical trial for VACCINEX, INC..
Vaccinex, Inc. is a clinical-stage biotechnology company developing targeted biotherapeutics, primarily its lead candidate pepinemab, for neurodegenerative diseases, cancer, and autoimmune disorders, with a focus on Alzheimer's disease and head and neck cancer.
- Lead product candidate pepinemab is in clinical development for Alzheimer's disease, head and neck cancer, pancreatic cancer, and breast cancer [sec_mda · as of 2025-04-15].
- Cash and cash equivalents were $1.1 million as of December 31, 2024, with total current assets of $2.5 million [sec_mda · as of 2025-04-15].
- Net loss for the year ended December 31, 2024 was $18.6 million, and accumulated deficit reached $358.6 million [sec_mda · as of 2025-04-15].
- The company has incurred significant net losses and negative cash flows from operations since inception in 2001 [sec_mda · as of 2025-04-15].
What works
- Vaccinex believes it is the leader in semaphorin 4D (SEMA4D) biology and the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders [sec_mda · as of 2024-11-14].
- Pepinemab is being studied across multiple indications, including Alzheimer's disease and several cancers, through company-sponsored and investigator-sponsored trials [sec_mda · as of 2025-04-15].
- The company has developed proprietary platform technologies, including the SEMA4D antibody platform and ActivMAb antibody discovery platform, to support pipeline expansion and partnerships [sec_mda · as of 2024-11-14].
What to weigh
- Cash and cash equivalents of $1.1 million as of December 31, 2024 are projected to be insufficient to sustain operations through one year from the financial statement issuance date [sec_mda · as of 2025-04-15].
- The company has an accumulated deficit of $358.6 million as of December 31, 2024, with recurring net losses and negative cash flows from operations [sec_mda · as of 2025-04-15].
- Vaccinex expects to need additional financing to continue operations, and such capital may not be available on reasonable terms [sec_mda · as of 2025-04-15].
- The company faces substantial doubt about its ability to continue as a going concern within one year after the issuance of its financial statements [sec_mda · as of 2024-11-14].
From the filings
Quoted directly from source documents.
Cash and cash equivalents were $1.1 million as of December 31, 2024.
“As of December 31, 2024, and 2023, our principal source of liquidity was cash and cash equivalents in the amount of $1.1 million and $1.5 million, respectively.”
SEC MD&A · April 15, 2025
Net loss for 2024 was $18.6 million.
“For the years ended December 31, 2024, and 2023, we reported a net loss of $18.6 million and $20.3 million, respectively.”
SEC MD&A · April 15, 2025
Accumulated deficit was $358.6 million as of December 31, 2024.
“As of December 31, 2024, and December 31, 2023, we had an accumulated deficit of $358.6 million and $339.9 million, respectively.”
SEC MD&A · April 15, 2025
The company believes it is the leader in SEMA4D biology.
“We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders.”
SEC MD&A · November 14, 2024
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash of $1.1M as of Dec 31, 2024 is projected insufficient to sustain operations through one year [sec_mda · as of 2025-04-15].
- Need for additional capital — Company expects to seek additional financing; capital may not be available on reasonable terms [sec_mda · as of 2025-04-15].
- History of losses — Accumulated deficit of $358.6M as of Dec 31, 2024, with recurring net losses since inception [sec_mda · as of 2025-04-15].
- Clinical-stage uncertainty — All product candidates are in clinical or earlier development; no approved products or commercial revenue [sec_mda · as of 2025-04-15].
What to watch
- Ability to secure additional financing to continue operations beyond the current cash runway [sec_mda · as of 2025-04-15].
- Clinical trial results for pepinemab in Alzheimer's disease and head and neck cancer [sec_mda · as of 2025-04-15].
- Progress of earlier-stage candidates VX5 (CXCL13 Mab) and CXCR5 Mab [sec_mda · as of 2024-11-14].
- Potential strategic partnerships, licensing deals, or government funding to support pipeline development [sec_mda · as of 2025-04-15].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run VACCINEX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VACCINEX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.2 months
OCF -$4M · Net income -$3M
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 22, 2026- % of float
- 3.2%
- Days to cover
- 0.6
- Shares short
- 62,111
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VCNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for VACCINEX, INC.?
Vaccinex, Inc. is a clinical-stage biotechnology company developing targeted biotherapeutics, primarily its lead candidate pepinemab, for neurodegenerative diseases, cancer, and autoimmune disorders, with a focus on Alzheimer's disease and head and neck cancer.
What is VACCINEX, INC.'s lead drug candidate?
VACCINEX, INC.'s most advanced tracked candidate is chs-114 (Phase 1) for Cancer immunotherapy.
Who is the CEO of VACCINEX, INC.?
Dr. Maurice Zauderer Ph.D. is the chief executive officer of VACCINEX, INC. (VCNX).
Where is VACCINEX, INC. headquartered?
VACCINEX, INC. (VCNX) is headquartered in Rochester, NY, United States.
What therapeutic areas does VACCINEX, INC. focus on?
VACCINEX, INC. develops therapies across Oncology, Rare Disease, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.